RenovoRx Inc. has received a deficiency notice from the Nasdaq Stock Market for failing to maintain the minimum $1.00 bid price required for continued listing on the Nasdaq Capital Market. The company's stock traded below this threshold for 32 consecutive business days, prompting the notice. RenovoRx has until June 30, 2026, to regain compliance by achieving a closing bid price of at least $1.00 per share for ten consecutive business days. If the company does not meet this requirement, it may be eligible for an additional 180-day compliance period, provided it meets other listing standards and notifies Nasdaq of its intentions to cure the deficiency, potentially through a reverse stock split. Failure to comply could result in delisting, though the company would have the right to appeal. The notice does not have an immediate effect on the company’s stock listing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-000113), on January 02, 2026, and is solely responsible for the information contained therein.